University of Munich, 1957, Physikum
University of Freiburg, 1960, State Medical Examination
University of Freiburg, 1960, MD
Transplantation biology; basic and translational research into the biology of allogeneic blood and marrow hematopoietic cell transplantation (HCT)
Developing radically different approaches for HCT that have minimal toxicity, do not ablate the marrow, and thus are safe enough to administer in the ambulatory care setting.
Extending treatment with HCT from related and unrelated donors to include elderly and medically infirm patients with advanced hematologic malignancies and eradicating underlying disease with immunologic graft-vs-tumor effects.
Applying minimal-intensity conditioning regimens to treat patients with serious non-malignant blood disorders, such as aplastic anemia, hemoglobinopathies and immune deficiency diseases, by allogeneic HCT.
Develop novel methods for preventing acute GVHD and treating chronic GVHD in animal models based on mechanistic studies.
Investigating graft-host tolerance by establishing transient mixed hematopoietic chimerism as a prelude for acceptance of solid organ transplants.
Allogeneic HCT for patients with advanced malignant and non-malignant blood disorders
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.